Pain management

Strainsforpains, Inc. secures its largest orders to date from NYC establishments

Retrieved on: 
Friday, January 19, 2024
Patient, Hospital, Pain management, Force of nature, Nursing, International Cannabinoid Research Society, Absorption, Myalgia, Security (finance), Media, Physician, 3D printing

Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various CBD and health markets, including Forces of Nature, Portokali, and other prominent establishments in New York City.

Key Points: 
  • Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various CBD and health markets, including Forces of Nature, Portokali, and other prominent establishments in New York City.
  • This significant achievement marks a major milestone for our company and underscores the increasing demand for Strainsforpains’ high-quality products.
  • With this significant order, Strainsforpains will deliver its full spectrum topical CBD products, renowned for their exceptional quality and effectiveness.
  • The company continues its collaboration with Popped, a NYC company, to jointly develop products and services with anticipated sales of six hundred thousand dollars by the end of 2024.

Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence

Retrieved on: 
Thursday, January 18, 2024
Freedom, Patient, PNS, Sure, Collection, Partnership, Pain management, Chronic pain, Physician, Nursing

Curonix’s Freedom® Peripheral Nerve Stimulation (PNS) provides lasting chronic pain relief through a non-opioid, minimally invasive implanted technology.

Key Points: 
  • Curonix’s Freedom® Peripheral Nerve Stimulation (PNS) provides lasting chronic pain relief through a non-opioid, minimally invasive implanted technology.
  • Paired with Sure Med’s digital health platform, Perspectives in Care, Curonix will partner with physicians and their teams to collect and analyze PNS data to expand the body of clinical evidence to further support PNS efficacy.
  • Sure Med partners with forward-thinking companies to work toward solutions to help end the opioid overdose epidemic through greater compliance in pain management settings.
  • “There is a need for clinical data and outcomes to make it easier for physicians and patients to navigate a patient's chronic pain journey,” said John Bowman, Founder and CEO of Sure Med Compliance.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Paragon Anesthesiology, the Largest Private Anesthesia Group Serving Northeastern Tennessee and Southwestern Virginia, Chooses Aidéo Technologies to Streamline Mid-Revenue Cycle Operations and Create Medical Coding Capacity

Retrieved on: 
Thursday, January 25, 2024
Artificial intelligence, Patient, Multimedia, Pain management, American Academy, AI, P.C, Paris Las Vegas, Programmer, Gemini, PALM, Physician, Growth, Medical device

Paragon Anesthesia is a new practice group formed by Anesthesia and Pain Consultants, P.C.

Key Points: 
  • Paragon Anesthesia is a new practice group formed by Anesthesia and Pain Consultants, P.C.
  • Both practices have served patients in Bristol and Johnson City, TN, and the greater Tri-Cities and Southwest VA areas for more than 30 years.
  • The recent merger has led to new growth within the practice leading to a need to streamline operations and seek efficiencies.
  • Aidéo Technologies is a leading provider of AI-powered medical coding productivity solutions to the revenue cycle management industry.

nen Introduces Its First Groundbreaking Product "nendo" for Pediatric Pain

Retrieved on: 
Friday, January 19, 2024
Hope, Patient, Pain management, Nen, Cancer, Quality of life, Food, Child, Pain, Parent, Toy

BARCELONA, Spain, Jan. 19, 2024 /PRNewswire/ -- This revolutionary digital program aims to provide young patients with cancer an innovative way to address their pain through gamified behavioral techniques.

Key Points: 
  • nen, a pioneer in digital health solutions, is thrilled to announce the launch of its first product, "nendo", specifically designed for children suffering from pain.
  • nendo harnesses the power of play, combining behavioral techniques and gamification, to offer a unique approach to pain management enhancing kids overall quality of life.
  • The platform helps children to restructure beliefs and emotional reactions to pain and improve their overall wellbeing.
  • By leveraging gamification and behavioral techniques, we believe nendo can help manage pain and significantly improve the well-being of these children.

VMX 2024 Showcased Groundbreaking Innovations in Veterinary Medicine to Provide the Best Care for Pets Around the World

Retrieved on: 
Thursday, January 18, 2024
Hill, Research, MRI, Animal, VMX, Pain management, Otter, Magic, Expo Hall, Horse, DVM, World's fair, Diagnosis, Veterinarian, Roger Hawkins (drummer), Osteoarthritis, Diabetes, Pet, DEI, Radiology, Bacteria, OA, Disease, Education, Artificial intelligence, Veterinary medicine, CAE, AI, Quality of life, Fantasy, Cat, Dog, CE, Patient, Internal medicine, Texas A&M University, The Show of Shows, Respiratory disease, Nap, FDA, Pet industry

ORLANDO, Fla. , Jan. 18, 2024 /PRNewswire/ -- The North American Veterinary Community (NAVC) concluded its 41st annual Veterinary Meeting and Expo (VMX 2024) Jan. 17, kicking off the new year with the latest product introductions and innovations and setting the direction for the $104 billion animal health care industry in 2024. More than 27,000 people attended the event from 82 countries with 8,700 first-time attendees. Nearly 26,000 were in person, representing a local economic impact exceeding $65.3 million.

Key Points: 
  • "VMX 2024 was truly the Show of Shows and brought the best in education and new technologies and products that are transforming veterinary medicine, plus invaluable networking opportunities and headlining entertainment.
  • "At the end of the day, what we're trying to do is provide the best care for pets around the world.
  • "At VMX 2024, we saw things that once sounded like fantasy now become a reality," said NAVC Chief Veterinary Officer Dana Varble, DVM, CAE.
  • Technology to assess animal pain and help pet owners and veterinary professionals provide the best care to all companion animals.

Healing Heel Pain: Researchers from Sahmyook University Explore the Use of Local Vibration in Plantar Fasciitis Treatment

Retrieved on: 
Thursday, January 18, 2024
Research, Associate, Ultrasound, Sahmyook University, Foot, Pain management, Anatomical terms of location, ESWT, Journal, Tears, Pain, Active, Randomized controlled trial, Heel, Motivation, Physical medicine and rehabilitation, Physical therapy, Medical imaging

SEOUL, South Korea, Jan. 18, 2024 /PRNewswire/ -- Plantar fasciitis (PF) is a common musculoskeletal, inflammatory condition, characterized by severe pain in the heel of the foot, to the extent that it limits day-to-day activities. The plantar fascia ligament, a fibrous connecting tissue, supports the arch of the foot and functions as a shock absorber, similar to modern-day car suspension systems. With increased activity, the ligament can experience tears and damage, leading to the development of PF.

Key Points: 
  • Treatment for PF includes pain management through anti-inflammatory drugs, stretching exercises, night-splint therapy, steroidal medications, and extracorporeal shock wave therapy (ESWT).
  • Interestingly, their study revealed the combination of local vibration and extra-corporeal shock therapy as an effective approach for treating chronic plantar fasciitis.
  • One group received a combination of local vibration (LV) and ESWT, while the other group underwent ESWT alone.
  • Title of original paper: Effects of Local Vibration Combined with Extracorporeal Shock Wave Therapy in Plantar Fasciitis: A Randomized Controlled Trial

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Retrieved on: 
Wednesday, January 17, 2024
Senior, North American Neuromodulation Society, HFX, Patient, Medicine, PST, NANS, Pain management, University, Nervous system, Spinal cord stimulator, SCS, Chronic pain, Caesars Palace, Annual general meeting, Research fellow, University of Arkansas, Plenary session, Hertz, Dentistry

REDWOOD CITY, Calif., Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.

Key Points: 
  • Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.
  • A total of 25 scientific abstracts reviewing clinical results for 10 kHz Therapy™, including four podium presentations and 21 posters, will be presented at the conference.
  • "The growing body of clinical evidence from our 25 scientific abstracts displays the substantial benefits of 10 kHz Therapy and we look forward to continuing to treat underserved patient populations suffering from debilitating chronic pain."
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

Osteoarthritis Therapeutics Market to grow by USD 3.96 billion from 2022-2027, North America to account for 32% of market growth - Technavio

Retrieved on: 
Wednesday, January 17, 2024
Obesity, X-ray, Regenerative medicine, Osteoarthritis, Risk, Therapy, Research, MRI, Pressure, ROW, Analgesic, NSAID, Health, Pain management, FREE, Nonsteroidal anti-inflammatory drug, Disease, Pfizer, Eli Lilly, Nonsteroidal, Drug development, USD, Ulcer, Burns, Biomarker, DSM-IV codes, Inflammation, Rheumatology, Ageing, Growth, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.
  • North America will contribute 32% to the growth of the global market during the forecast period.
  • Such diagnostic advancements not only aid in understanding drug effectiveness but also drive growth in the osteoarthritis therapeutics market.
  • Growth of the osteoarthritis therapeutics market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of osteoarthritis therapeutics market vendors.